These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21356265)

  • 21. Site-directed mutagenesis of the putative distal helix of peroxygenase cytochrome P450.
    Matsunaga I; Ueda A; Sumimoto T; Ichihara K; Ayata M; Ogura H
    Arch Biochem Biophys; 2001 Oct; 394(1):45-53. PubMed ID: 11566026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation.
    Iida I; Miyata A; Arai M; Hirota M; Akimoto M; Higuchi S; Kobayashi K; Chiba K
    Drug Metab Dispos; 2004 Jan; 32(1):7-9. PubMed ID: 14709614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electrochemical characterisation of the human cytochrome P450 CYP2C9.
    Johnson DL; Lewis BC; Elliot DJ; Miners JO; Martin LL
    Biochem Pharmacol; 2005 May; 69(10):1533-41. PubMed ID: 15857618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P450 on drugs.
    Jabri E
    Nat Struct Biol; 2003 Aug; 10(8):587. PubMed ID: 12886290
    [No Abstract]   [Full Text] [Related]  

  • 25. Prediction of metabolism by cytochrome P450 2C9: alignment and docking studies of a validated database of substrates.
    Sykes MJ; McKinnon RA; Miners JO
    J Med Chem; 2008 Feb; 51(4):780-91. PubMed ID: 18237107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crystal structure of human cytochrome P450 2C9 with bound warfarin.
    Williams PA; Cosme J; Ward A; Angove HC; Matak Vinković D; Jhoti H
    Nature; 2003 Jul; 424(6947):464-8. PubMed ID: 12861225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians.
    DeLozier TC; Lee SC; Coulter SJ; Goh BC; Goldstein JA
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1085-90. PubMed ID: 16099926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversible binding of antidiabetic drugs, repaglinide and gliclazide, with human serum albumin.
    Seedher N; Kanojia M
    Chem Biol Drug Des; 2008 Oct; 72(4):290-6. PubMed ID: 18844675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of a mutated residue at the entrance of the substrate access channel in cytochrome p450 engineered for vitamin D(3) hydroxylation activity.
    Fukunishi H; Yagi H; Kamijo K; Shimada J
    Biochemistry; 2011 Oct; 50(39):8302-10. PubMed ID: 21877691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites.
    Ahlström MM; Ridderström M; Zamora I
    J Med Chem; 2007 Nov; 50(22):5382-91. PubMed ID: 17915853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploration of the binding of curcumin analogues to human P450 2C9 based on docking and molecular dynamics simulation.
    Shi R; Wang Y; Zhu X; Lu X
    J Mol Model; 2012 Jun; 18(6):2599-611. PubMed ID: 22076061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydrophobic side chain requirements for lauric acid and progesterone hydroxylation at amino acid 113 in cytochrome P450 2C2, a potential determinant of substrate specificity.
    Straub P; Johnson EF; Kemper B
    Arch Biochem Biophys; 1993 Nov; 306(2):521-7. PubMed ID: 8215458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
    Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
    Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.
    Zhou K; Donnelly L; Burch L; Tavendale R; Doney AS; Leese G; Hattersley AT; McCarthy MI; Morris AD; Lang CC; Palmer CN; Pearson ER
    Clin Pharmacol Ther; 2010 Jan; 87(1):52-6. PubMed ID: 19794412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes.
    Ho PC; Abbott FS; Zanger UM; Chang TK
    Pharmacogenomics J; 2003; 3(6):335-42. PubMed ID: 14597963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2C9 genotype as a predictor of drug disposition in humans.
    Lee CR
    Methods Find Exp Clin Pharmacol; 2004; 26(6):463-72. PubMed ID: 15349140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone.
    Hummel MA; Gannett PM; Aguilar J; Tracy TS
    Arch Biochem Biophys; 2008 Jul; 475(2):175-83. PubMed ID: 18485885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential activation of CYP2C9 variants by dapsone.
    Hummel MA; Dickmann LJ; Rettie AE; Haining RL; Tracy TS
    Biochem Pharmacol; 2004 May; 67(10):1831-41. PubMed ID: 15130760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant.
    Hummel MA; Locuson CW; Gannett PM; Rock DA; Mosher CM; Rettie AE; Tracy TS
    Mol Pharmacol; 2005 Sep; 68(3):644-51. PubMed ID: 15955872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
    Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
    Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.